These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 28586272)

  • 1. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
    Landmann EC; Walker UA
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
    Walsh GM
    Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cryopyrin-associated periodic syndromes].
    Quartier P; Rodrigues F; Georgin-Lavialle S
    Rev Med Interne; 2018 Apr; 39(4):287-296. PubMed ID: 29111302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cryopyrin-associated periodic syndromes: diagnosis and management.
    Miyamae T
    Paediatr Drugs; 2012 Apr; 14(2):109-17. PubMed ID: 22335455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Mutation in the Pyrin Domain of the NOD-like Receptor Family Pyrin Domain Containing Protein 3 in Muckle-Wells Syndrome.
    Hu J; Zhu Y; Zhang JZ; Zhang RG; Li HM
    Chin Med J (Engl); 2017 Mar; 130(5):586-593. PubMed ID: 28229991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gain of function mutation and inflammasome driven diseases in human and mouse models.
    Cordero MD; Alcocer-Gómez E; Ryffel B
    J Autoimmun; 2018 Jul; 91():13-22. PubMed ID: 29610014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early canakinumab therapy for the sensorineural deafness in a family with Muckle-Wells syndrome due to a novel mutation of NLRP3 gene.
    Iida Y; Wakiguchi H; Okazaki F; Nakamura T; Yasudo H; Kubo M; Sugahara K; Yamashita H; Suehiro Y; Okayama N; Hashimoto K; Iwamoto N; Kawakami A; Aoki Y; Takada H; Ohga S; Hasegawa S
    Clin Rheumatol; 2019 Mar; 38(3):943-948. PubMed ID: 30338413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
    Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
    Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
    Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
    Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
    Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of IL-1 inhibition on fatigue associated with autoinflammatory syndromes.
    Yadlapati S; Efthimiou P
    Mod Rheumatol; 2016; 26(1):3-8. PubMed ID: 26140469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryopyrin-associated periodic syndromes: background and therapeutics.
    Kubota T; Koike R
    Mod Rheumatol; 2010 Jun; 20(3):213-21. PubMed ID: 20140476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CAPS: cryopyrin-associated periodic syndrome].
    Saito MK
    Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(5):369-77. PubMed ID: 22041424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CAPS treatment].
    Jiménez Treviño S; Ramos Polo E
    Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
    Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
    Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anakinra for cryopyrin-associated periodic syndrome.
    Koné-Paut I; Galeotti C
    Expert Rev Clin Immunol; 2014 Jan; 10(1):7-18. PubMed ID: 24308832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muckle-Wells Syndrome: A Case Report with an NLRP3 T348M Mutation.
    Naz Villalba E; Gomez de la Fuente E; Caro Gutierrez D; Pinedo Moraleda F; Yanguela Rodilla J; Mazagatos Angulo D; López Estebaranz JL
    Pediatr Dermatol; 2016 Sep; 33(5):e311-4. PubMed ID: 27435956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
    Church LD; McDermott MF
    Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating inflammation by blocking interleukin-1 in humans.
    Dinarello CA; van der Meer JW
    Semin Immunol; 2013 Dec; 25(6):469-84. PubMed ID: 24275598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.